Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 6
2018 20
2019 17
2020 12
2021 9
2022 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Economic Cost and Sustainability of Oral Therapies in Precision Oncology.
Desai AP, Scheckel CJ, Soderberg LC, Jensen CJ, Orme JJ, Tella SH, Kommalapati A, Pritchett JC, Khera N, Mahipal A, Go RS; Mayo Clinic Hematology and ONcology Outcomes Research (HONOR) Group. Desai AP, et al. Among authors: kommalapati a. JCO Oncol Pract. 2022 Aug;18(8):e1247-e1254. doi: 10.1200/OP.21.00847. Epub 2022 May 26. JCO Oncol Pract. 2022. PMID: 35617640
Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Barata A, et al. Among authors: kommalapati a. Transplant Cell Ther. 2022 Jul;28(7):401.e1-401.e7. doi: 10.1016/j.jtct.2022.05.015. Epub 2022 May 14. Transplant Cell Ther. 2022. PMID: 35580732 Free PMC article.
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
Hoogland AI, Barata A, Logue J, Kommalapati A, Hyland KA, Nelson AM, Eisel SL, Small BJ, James BW, Christy SM, Bulls HW, Booth-Jones M, Jayani RV, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Hoogland AI, et al. Among authors: kommalapati a. Transplant Cell Ther. 2022 Jun;28(6):305.e1-305.e9. doi: 10.1016/j.jtct.2022.03.023. Epub 2022 Apr 1. Transplant Cell Ther. 2022. PMID: 35378330 Free PMC article.
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. O'Sullivan CC, et al. Among authors: kommalapati a. Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12. Future Oncol. 2021. PMID: 34636255 Free PMC article.
Management of well-differentiated neuroendocrine tumors.
Tella SH, Starr JS, Kommalapati A, Sonbol MB, Halfdanarson TR. Tella SH, et al. Among authors: kommalapati a. Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593. Clin Adv Hematol Oncol. 2021. PMID: 34495022 Review.
61 results